CYP19A1 and breast carcinoma: Endocrine therapies such as tamoxifen and aromatase inhibitors have been shown to increase bone loss or fracture risk in both pre- and postmenopausal women with early-stage breast cancer (Powles et al., 1996; Sverrisdóttir et al., 2004; Aihara et al., 2010; Zaman et al., 2012; Tseng et al., 2018).